TD Asset Management Inc Raises Holdings in BioNTech SE Sponsored ADR $BNTX

TD Asset Management Inc raised its position in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 1,417.6% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 173,795 shares of the company’s stock after purchasing an additional 162,343 shares during the period. TD Asset Management Inc owned 0.07% of BioNTech worth $18,513,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Banque Cantonale Vaudoise acquired a new stake in shares of BioNTech in the first quarter valued at about $36,000. LRI Investments LLC raised its holdings in BioNTech by 234.6% in the 2nd quarter. LRI Investments LLC now owns 445 shares of the company’s stock valued at $47,000 after acquiring an additional 312 shares during the last quarter. Banque Transatlantique SA acquired a new stake in BioNTech in the 1st quarter valued at about $80,000. Costello Asset Management INC purchased a new position in BioNTech in the 1st quarter worth approximately $91,000. Finally, Goodman Advisory Group LLC acquired a new position in shares of BioNTech during the 1st quarter worth approximately $105,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on BNTX shares. Wells Fargo & Company set a $150.00 price target on BioNTech and gave the company an “overweight” rating in a report on Tuesday, August 5th. Morgan Stanley cut their target price on BioNTech from $133.00 to $131.00 and set an “overweight” rating for the company in a research note on Friday, October 10th. Bank of America boosted their price target on shares of BioNTech from $126.00 to $134.00 and gave the company a “buy” rating in a research report on Tuesday, August 5th. HC Wainwright restated a “buy” rating and set a $136.00 price objective on shares of BioNTech in a research report on Monday, September 8th. Finally, JPMorgan Chase & Co. lifted their target price on shares of BioNTech from $116.00 to $121.00 and gave the stock a “neutral” rating in a research note on Monday, September 22nd. Ten investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, BioNTech currently has a consensus rating of “Moderate Buy” and a consensus price target of $134.32.

BioNTech Price Performance

BNTX stock opened at $105.14 on Friday. BioNTech SE Sponsored ADR has a 52-week low of $81.20 and a 52-week high of $129.27. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01. The stock has a market cap of $25.28 billion, a price-to-earnings ratio of -65.71 and a beta of 1.45. The business has a fifty day moving average of $103.76 and a two-hundred day moving average of $103.88.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, August 4th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($1.41) by ($0.19). The business had revenue of $306.46 million during the quarter, compared to analyst estimates of $161.26 million. BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The business’s revenue for the quarter was up 102.6% on a year-over-year basis. During the same period last year, the company earned ($3.36) EPS. BioNTech has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.